Home › Compare › NICFF vs ABBV
NICFF yields 5.30% · ABBV yields 3.06%● Live data
📍 NICFF pulled ahead of the other in Year 3
Combined, NICFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NICFF + ABBV for your $10,000?
Nichias Corporation manufactures and sells thermal insulation materials primarily in Japan. It operates in five segments: Energy and Industrial Plants, Industrial Products, Advanced Products, Autoparts, and Building Materials. The company offers gaskets and packings, including non-asbestos gaskets and packings, rubber type gaskets, other seal products, and peripheral function materials; and thermal insulation materials, such as fiber products, high performance thermal insulation materials, heat-insulation boards, and cryogenic insulation materials, as well as thermal insulation materials for molten aluminum. It also provides various fluoropolymer materials, processed products, and corrosion-resistant linings, as well as tubes, hoses, and bellows; filter products and environmental equipment; and auto parts comprising sealing materials, retaining parts/materials, and sound-proofing parts/materials, as well as heat-protection products, control parts, and materials. In addition, the company offers building materials for buildings and housing; and undertakes hot and cold insulation, refractory, electric heater tracing, acoustic insulation, and aerogel heat-insulation works. Further, it provides furniture sliding pads, and friction and agricultural materials. The company serves electric power and gas; waste incineration plants; chemical, petroleum refinery, and petrochemical; steel and non-ferrous metals; aluminum casting and processing; paper; building and housing construction; semiconductor and flat panel display; foods and pharmaceutical; medical equipment; electric equipment; aerospace; automobiles; ship building, maintenance, and repair; industrial equipment; and others industries. Nichias Corporation was incorporated in 1896 and is headquartered in Tokyo, Japan.
Full NICFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.